Cipla gets approval for Testosterone Cypionate Injection

21 Jun 2018 Evaluate

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Testosterone Cypionate Injection 100mg/ml and 200mg/ml from the United States Food and Drug Administration (USFDA).

Cipla’s Testosterone Cypionate Injection 100mg/ml and 200mg/ml is AO-rated generic therapeutic equivalent version of Pharmacia and Upjohn’s Depo-Testosterone. It is indicated for replacement therapy in males in conditions associated with symptoms of deficiency or absence of endogenous testosterone.

According to IQVIA (IMS Health), Depo-Testosterone and its generic equivalents had US sales of approximately $191 million for the 12 month period ending April 2018.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1327.00 -24.85 (-1.84%)
04-Mar-2026 11:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1742.30
Dr. Reddys Lab 1285.00
Cipla 1327.00
Zydus Lifesciences 891.00
Lupin 2281.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×